Anesiva insitate Phase II trual of Adlea in Arthroscopic Shoulder Surgery « GPCR News

Tags
5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
July 2008

M T W T F S S

« Jun Aug »

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30 31

Anesiva insitate Phase II trual of Adlea in Arthroscopic Shoulder Surgery

Posted on July 17, 2008 by crimsoncanary

Anesiva have begun a Phase II clinical trial of Adlea, the company’s long-acting capsaicin product in for the management of acute pain in patients undergoing arthroscopic shoulder surgery involving rotator cuff repair.

Filed under: gpcr | Tagged: Adlea, agonist, ALGRX-4975, ALGRX4975, Anesiva, phase II, Vanilloid, VR1

« Nile Therapeutics begin Phase IIa with CD-NP in Heart Failure Patients Irribow (ramosetron) approved in Japan for diarrhea predominant IBS »

Leave a Reply